| Patients with IM primary resistance (n = 20) | Patients with IM secondary resistance (n = 6) | Patients nilotinib-treated (n = 16) | Patients dasatinib-treated (n = 10) | patients achieved their CCyR (n = 10) | patients not achieved their CCyR (n = 16) | |
G2677T/A genotypes, n (%) | GG | 6 (66.7) | 3 (33.3) | 6 (66.7) | 3 (33.3) | 4 (44.4) | 5 (55.6) |
GT | 9 (75) | 3 (25) | 7 (58.3) | 5 (41.7) | 5 (41.7) | 7 (58.3) | |
TT | 1 (100) | 0(0) | 1 (100) | 0(0) | 1 (100) | 0(0) | |
AA | 4 (100) | 0 (0) | 2 (50) | 2 (50) | 0 (0) | 4 (100) | |
(1236-2677-3435) haplotypes of MDR1 gene, n (%) | CGC | 11 (64.7) | 6 (35.3) | 10 (58.8) | 7 (41.2) | 8 (47) | 9 (53) |
CGT | 2 (100) | 0 (0) | 2 (100) | 0(0) | 2 (50) | 2 (50) | |
CTC | 2 (100) | 0 (0) | 2 (100) | 0(0) | 0(0) | 2 (100) | |
CAC | 5 (100) | 0 (0) | 2 (40) | 3 (60) | 0(0) | 5 (100) |